GLP-1 Market and Competitive Landscape

Comprehensive coverage of GLP-1 receptor agonist market dynamics, including Eli Lilly's portfolio (Zepbound, Mounjaro), competitive positioning against Novo Nordisk, clinical efficacy comparisons, pipeline developments, regulatory considerations, and market expansion into obesity, diabetes, and other therapeutic areas.